Gene Spectrum and Clinical Traits of Nine Patients With Oocyte Maturation Arrest.

Background: Oocyte maturation arrest is a disease that produces immature oocytes and cannot be mature after culturing in vitro, which leads to female primary infertility. We aimed to summarize nine representative patients in our center to retrospectively analyze the genetic variants and clinical characteristics of oocyte maturation arrest.
Methods: This study examined and analyzed nine families with oocyte maturation arrest. Whole-exome sequencing (WES) of the probands was performed to detect the pathogenic variants. Sanger sequencing verified the WES findings in patients and available parents. ExAC database was used to search the variant frequency. The variants were assessed by pathogenicity and conservational property prediction analysis and according to the American College of Medical Genetics and Genomics (ACMG). Phenotypes of oocytes were evaluated by a light microscopy, and the phenotype-genotype correlation was also evaluated.
Results: Nine pathogenic variants in five genes were detected in nine patients, of which three were novel variants, including PATL2 [c.1374A > G (p. Ile458Met)] and [1289-1291del TCC (p. Leu430del)] and ZP2 [c.1543C > T (p. Pro515Ser)]. Nine variants were predicted to be pathogenic, resulting in different types of oocyte maturation arrest and clinical phenotypes.
Conclusion: Three novel pathogenic variants were identified, enabling the expansion of the gene variant spectrum. The related pathogenic mutations of the PATL2, TUBB8, and ZP1∼3 genes were highly suggestive of being causative of oocyte maturation arrest.

Introduction

Oocyte maturation is an important prerequisite for successful fertilization and embryonic development. Oocyte maturation includes cytoplasmic maturation and nuclear maturation (Swain and Pool, 2008). Cytoplasmic maturation is characterized by cytoplasmic changes required for cell fertilization, activation, and embryonic development. Furthermore, the sign of nuclear maturation is the rupture of germinal vesicles and the exclusion of the first polar body (Krisher, 2004; Sirard et al., 2006). Errors in any link may lead to oocyte maturation block, fertilization failure, and early embryo arrest, resulting in primary infertility. In 1990, Rudak et al. described the first patient of oocyte maturation arrest (Rudak et al., 1990). Depending on the stage of oocyte meiosis, there are four types of maturation failure, including arrest at germinal vesicle (GV), metaphase I (MI), and metaphase II (MII) and a mixed arrest with oocytes at multiple meiotic stages (Beall et al., 2010).

At present, there are six different types of oocyte maturation arrest in genetics. Oocyte maturation arrest type 1 (OMIM195000) is caused by ZP1 mutation, leading to the loss of zona pellucida (ZP) (Huang et al., 2014). Type 2 (OMIM616768) is caused by TUBB8 mutation. TUBB8 encodes the main tubulin isotype that assembles the spindle of human oocytes. Once interrupted, abnormal spindles can be seen and the cleavage of oocytes terminates at the MI stage (Zhao et al., 2020). Type 3 (OMIM182889) is oocyte degeneration caused by zona pellucida deletion and ‘empty follicle syndrome (EFS)’ (Chen et al., 2017c), which was associated with ZP3 gene mutation. EFS means in vitro fertilization (IVF) treatment. Although the number and size of follicles are normal, oocytes cannot be obtained after repeated ovarian stimulation (Coulam et al., 1986). Type 4 (OMIM614661) is mainly characterized by the arrest of oocyte development at the GV or MI stage, caused by PATL2 mutation (Chen et al., 2017a). Type 5 (OMIM614084) associated with the WEE2 gene mainly stagnates oocytes at the MII phase (Sang et al., 2018). Type 6 (OMIM182888) related to ZP2 mutation results in female primary infertility due to abnormal ZP of oocytes, which consequently results in poor binding with spermatozoa (Dai et al., 2019).

In this study, we recruited nine families. All females had a history of primary infertility and were diagnosed with oocyte maturation arrest. We found nine pathogenic variants in five genes, including the PATL2, TUBB8, and ZP1∼3 genes. We identified three novel mutation sites through whole-exome sequencing (WES) and analyzed the genetic causes of oocyte maturation arrest. All of these findings expand the genotypic spectrum of the PATL2 and ZP2 genes, which will lay the foundation for future genetic counseling.

Materials and Methods

Ethics Approval and Case Recruitment

This study was approved by the institutional review board (IRB) of the Center for Reproductive Medicine, The First Affiliated Hospital of Zhengzhou University (Ethic no. 2019-KY-166). All participants have provided written informed consent. We studied nine primary infertility females who were diagnosed with oocyte maturation arrest. Their parents were also studied for inheritance mode identification when available.

Whole-Exome Sequencing

Genomic DNA (gDNA) was extracted with QIAamp DNA Blood Mini Kit (QIAGEN, Germany, 51306) from peripheral blood following the manufacturer’s instructions. gDNA was quantified with the Quant-iT dsDNA HS Assay Kit (Invitrogen, Carlsbad, CA). MGIEasy exon capture V5 probe kit (BGI, China, 1000007746) was used for library construction and target region capturing. Library quality was measured by both Qubit 4 (Thermo Fisher Scientific, USA) and Bioanalyzer 2100 (Agilent, USA). After quality control, the libraries were pooled and sequenced to paired-end 100 bp on the MGISEQ-2000 system (MGI Technology Ltd. Co., China).

Variant Interpretation

PROVEAN (http://provean.jcvi.org), PolyPhen-2 (http://genetics.bwh.harvard.edu/), and SIFT (http://sift.jcvi.org) were used to predict the pathogenicity of the mutation site, and the ExAC (http://exac.broadinstitute.org/) database was used to search for the corresponding variant frequency. The conserved property of the variants was analyzed using UniProt (https://www.uniprot.org/). The pathogenicity interpretation of the variants followed the American College of Medical Genetics and Genomics (ACMG) recommendations.

Evaluation of Oocyte and Embryo Phenotype

Oocytes were obtained from the patients undergoing IVF or intracytoplasmic sperm injection (ICSI). The morphology of oocytes and embryonic development were observed by a light microscope. We studied the relationship between phenotype and genotype by clinical tests and the clinical records of the patients.

Results

Mutational Spectrum and Phenotypes in PATL2

In family 1, the 32-year-old woman suffered from primary infertility for 10 years, although with a normal menstrual period and normal semen parameters for her partner. The patient experienced three IVF/ICSI cycles. Her first IVF treatment used an early-follicular phase long-acting gonadotropin-releasing hormone (GnRH) agonist long protocol, which captured eight oocytes: five were at the GV phase, two were at the MI phase, and one degenerated. Totally, 28 oocytes were obtained in the second ICSI treatment using a midluteal short-acting GnRH agonist long protocol, all of which were at the GV phase. In her third cycle, 16 oocytes were obtained using a modified early-follicular phase long-acting GnRH agonist long protocol, all of which were at the GV phase (Figure 1A). No embryos were available in the three IVF/ICSI cycles (Table 1).

FIGURE 1

Phenotypes of oocytes from patients with maturation arrest. (A) Oocyte at GV (family 1). (B) Oocyte at MI (family 5). (C) Oocyte at MII (family 9). (D) Oocyte without ZP (family 7).

TABLE 1

Clinical characteristics of patients and their retrieved oocytes.

Family	Age (years)	Duration of infertility (years)	Previous IVF/ICSI cycles	Total no. of oocytes retrieved	GV oocyte	MI oocyte	MII oocyte	Oocyte with abnormal morphology	Immature oocyte (unknown stage)	No. of usable embryos
1 (I458M)	32	10	3	52	49	2	0	0	0	0
(L430del)
2 (V179M)	31	3	2	5	0	5	0	0	0	0
3 (V229A)	30	8	1	6	2	4	0	0	0	0
4 (V179M)	42	12	2	12	0	7	0	1	4	0
5 (S176W)	28	7	2	31	1	28	0	0	2	0
6 (Q292*)	27	6	2	7	4	1	0	2	0	1
7 (A134T)	33	3	2	3	0	1	0	2	0	0
8 (P515S)	32	4	2	20	14	5	0	1	0	0
9 (V255M)	31	2	1	10	0	9	1	0	0	0

IVF, in vitro fertilization; ICSI, intracytoplasmic sperm injection; GV, germinal vesicle; MI, metaphase I; MII, metaphase II.

WES detected compound heterozygous variants c. 1374A > G (p. Ile458Met) and c.1289_1291delTCC (p. Leu430del) in the PATL2 gene, and both variants were verified by Sanger sequencing. Additionally, we also identified that variants c. 1374A > G (p. Ile458Met) and c.1289_1291delTCC were inherited from the father and mother, respectively, by Sanger sequencing (Figure 2A). These two variants were neither reported in the HGMD database nor publications. According to ACMG guidelines, c. 1374A > G and c.1289_1291delTCC were classified as likely pathogenic (Table 2). In silico prediction by PolyPhen-2 and PROVEAN suggested that both variants are deleterious. The variants of PATL2 were not reported in the ExAC browser (Table 3). The variant coordination and the conservation analysis among primate species are indicated in Figures 2B,C. The results showed that mutations in PATL2 are highly evolutionarily conserved among different primate species.

FIGURE 2

Genotypic features of family 1. (A) Pedigrees of family 1 with female infertility. Sanger sequencing confirmation is shown on the right of the pedigrees. The “=” sign indicates infertility, and black circles represent affected individuals. The “W” sign means wild type. (B) The positions of the novel mutations are indicated in the corresponding amino acids shown on the PATL2 protein. (C) Preservative mutation analysis for the novel sites in different species.

TABLE 2

The evidence item description according to ACMG.

Family	Variant	Gene	Interpretation	Conclusion
1	c.1374A > G: p. I458M	PATL2	PM1 a + PM2 b + PP2 c + PP4 d	Likely pathogenic
1	c.1289_1291delTCC: p. L430del	PATL2	PM1 + PM2 + PM4 e + PP4	Likely pathogenic
2	c.535G > A: p. V179M	TUBB8	PM1 + PM2 + PP2	Uncertain significance
3	c.686T > C: p. V229A	TUBB8	PM1 + PM2 + PP2 + PS3 f + PP1 g + PP4	Pathogenic
4	c.535G > A: p. V179M	TUBB8	PM1 + PM2 + PP2	Uncertain significance
5	c.527C > G: p. S176W	TUBB8	PM1 + PM2 + PP2 + PM5 h	Likely pathogenic
6	c.874C > T: p. Q292*	ZP1	PVS1 i + PM2+PM3 j + PP4	Pathogenic
7	c.400G > A: p. A134T	ZP3	PS3+PS4_Supporting k + PM2 +PP1_Moderate l	Pathogenic
8	c.1543C > T: p. P515S	ZP2	PM2	Uncertain significance
9	c.763G > A: p. V255M	TUBB8	PS4_Supporting + PM2+PM6 m + PP1_Moderate + PP2	Likely pathogenic

Note: the phenotype in the patient matches the gene’s disease association with reasonable specificity.

Note: pathogenicity classification has been made from a reputable source.

The variation is located in a mutational hot spot.

The frequency of the variant is less than 0.01 or absent from gnomAD, 1000 Genome Program, and ExAC databases.

Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.

Patient’s phenotype or family history is highly specific for a disease with a single genetic etiology.

Protein length changes due to in-frame deletions in a non-repeat region or stop-loss variants.

Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene.

Co-segregation with a disease in multiple affected family members in a gene definitively known to cause the disease.

Novel missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before.

The nonsense variant in a gene where loss of function is a known disease mechanism.

For recessive disorders, detected in trans with a pathogenic variant.

The prevalence of the variant in affected individuals is significantly increased compared to the prevalence in controls.

Co-segregation with disease in multiple affected family members in a gene definitively known to cause the disease. Note: it has stronger evidence with increasing segregation data.

Assumed de novo, but without confirmation of paternity and maternity.

TABLE 3

Overview of related mutations in the 9 families.

Family	Gene	Genomic coordination	cDNA change	Protein change	Variant type	Inheritance	PROVEAN a	PolyPhen-2 b	SIFT c	ExAC (total) d	ExAC (East Asian) d
1	PATL2	chr15:44959393	c.1374A > G	p. Ile458 Met	Missense	AR	N	PD	N	NA	NA
1	PATL2	chr15:44960613-44960616	c.1289_1291delTCC	p. Leu430del	In-frame deletion	AR	D	NA	NA	NA	NA
2	TUBB8	chr10:93797	c.535G > A	p. Val179Met	Missense	AD/AR	D	PD	D	8.322e-06	0
3	TUBB8	chr10:93646	c.686T > C	p. Val229 Ala	Missense	AD/AR	D	PD	D	NA	NA
4	TUBB8	chr10:93797	c.535G > A	p. Val179Met	Missense	AD/AR	D	PD	D	8.322e-06	0
5	TUBB8	chr10:93805	c.527C > G	p. Ser176Trp	Missense	AD/AR	D	PD	D	NA	NA
6	ZP1	chr11:60638477	c.874C > T	p. Gln292 e	Nonsense	AR	D	NA	NA	8.238e-05	0.0001
7	ZP3	chr7:76058 919	c.400G > A	p. Ala134Thr	Missense	AD	D	PD	D	NA	NA
8	ZP2	chr16:21212841	c.1543C > T	p. Pro515Ser	Missense	AR/AD e	D	PD	NA	NA	NA
9	TUBB8	chr10:93569	c.763G > A	p. Val255Met	Missense	AD/AR	N	PD	D	6.77e-05	0

AD, autosome dominant; AR, autosome recessive; N, neutral; D, deleterious; NA, not available.

Variant effect predicted by PROVEAN.

Variant effect predicted by PolyPhen-2.

Variant effect predicted by SIFT.

Frequency of corresponding variants in the total and East Asian population of ExAC.

OMIM database shows that ZP2 follows a recessive inheritance pattern and a recent study found it was also inherited in an autosomal dominant pattern (Yang et al., 2021).

Mutational Spectrum and Phenotypes in TUBB8

In family 2, the patient was a 31-year-old woman with a three-year history of primary infertility. In her two IVF cycles, five oocytes were retrieved, all at the MI stage, and failed to be fertilized. In family 4, the 42-year-old woman had a 12-year history of primary infertility. The patient underwent two IVF/ICSI cycles. In her first IVF cycle, an early-follicular phase long-acting GnRH agonist long protocol was adopted, eight oocytes were retrieved: seven were at MI and one was with abnormal morphology. In the second attempt with a midluteal short-acting GnRH agonist long protocol, four immature oocytes were obtained (unknown stage) as shown in Table 1.

The same variant c.535G > A (p.Val179Met) in exon 4 of the TUBB8 gene was found in these two patients by WES (Figures 3A,C). The site of c.535G > A was classified as an uncertain significance variant according to the ACMG guidelines (Table 2). The results of PROVEAN, PolyPhen-2, and SIFT prediction suggested that the mutation was pathogenic (Table 3).

FIGURE 3

Pedigrees of 5 families with TUBB8 variants. Sanger sequencing confirmation is shown on the right of the pedigrees. The “=” sign indicates infertility, and black circles represent affected individuals. The “W” sign means wild type, and question marks indicate the absence of a DNA sample. (A–E) represent different families.

In family 3, a 30-year-old woman had primary infertility for eight years. She underwent one ICSI cycle, which used a progestin-primed ovarian stimulation. Six oocytes were retrieved, including two GV and four MI oocytes (Table 1). All oocytes had fertilization failure because they were immature even after culturing 24 h in vitro. The WES detected variant c.686T > C (p.Val229Ala) in exon 4 of the TUBB8 gene (Figure 3B). The variant was interpreted as pathogenic according to the ACMG guidelines (Table 2). The results of PROVEAN, PolyPhen-2, and SIFT prediction suggested that the mutation was pathogenic (Table 3).

In family 5, the patient was a 28-year-old woman with a seven-year history of primary infertility. In the first IVF cycle, after an early-follicular phase long-acting GnRH agonist long protocol, 13 oocytes were retrieved, among which 11 were at the MI stage and 2 were immature oocytes (unknown stage). One oocyte developed into two pronuclei after fertilization, but no usable embryo was formed finally. In her second attempt, by a midluteal short-acting GnRH agonist long protocol, 18 oocytes were retrieved: one was at the GV stage and the rest were at the MI stage. They remained unmatured even after in vitro maturation (IVM) for 24 h (Table 1; Figure 1B). We found variant c.527C > G (p.Ser176Trp) in exon 4 of the TUBB8 gene by WES (Figure 3D). PROVEAN, PolyPhen-2, and SIFT predicted the missense variant as pathogenic, and according to the ACMG criteria, the variant was classified as likely pathogenic (Tables 2, 3).

In family 9, a 31-year-old woman had primary infertility for two years. In her first IVF cycle, after an early-follicular phase long-acting GnRH agonist long protocol, 10 oocytes were retrieved. Nine were at the MI stage and one was at the MII stage, but no usable embryos to transfer after fertilization (Table 1; Figure 1C). Missense variant c.763G > A (p.Val255Met) in Figure 3E, located in exon 4 of TUBB8, was predicted to be pathogenic by PolyPhen-2 and SIFT, and also according to the ACMG criteria, the variant was classified as a variant of likely pathogenic (Tables 2, 3).

Mutational Spectrum and Phenotypes in ZP1∼3

In family 6, a 27-year-old woman had a six-year history of primary infertility. The patient underwent two IVF/ICSI cycles. In her first cycle, using an early-follicular phase long-acting GnRH agonist long protocol, 11 follicles were monitored under the transvaginal ultrasound on the day of the human chorionic gonadotropin (hCG) trigger. However, only five oocytes were retrieved, four of which were at the GV stage (Supplementary Figure S1) and one was at the MI stage. The MI oocyte matured after IVM and formed a usable embryo, but her bloodβ-hcg test was negative two weeks after embryo transfer. In her second attempt using a midluteal short-acting GnRH agonist long protocol, seven follicles were monitored by transvaginal ultrasound on the hCG trigger day, but only two oocytes without ZP were obtained (Table 1), suggestive of EFS. A homozygous nonsense variant c.874C > T (p.Gln292∗) in exon 5 of ZP1 was detected by WES. This variant was further confirmed to be inherited from her parents by Sanger sequencing (Figure 4A). PROVEAN predicted the nonsense variant to be pathogenic, and according to the ACMG criteria, the variant was classified as pathogenic (Tables 2, 3).

FIGURE 4

Genotypic features of ZP1 ∼ 3. (A–C) Pedigrees of the families with ZP1 ∼ 3 variants. Sanger sequencing confirmation is shown on the right of the pedigrees. The “=” sign indicates infertility, and black circles represent affected individuals. The “W” sign means wild type, and question marks indicate the absence of a DNA sample. (D) Preservative mutation analysis for the novel site of ZP2 in different species. (E) The position of the novel mutation is indicated in the corresponding amino acids shown on the ZP2 protein.

In family 7, a 33-year-old woman had primary infertility for three years. In her first IVF cycle using an early-follicular phase long-acting GnRH agonist long protocol, one oocyte was retrieved, which was at the MI stage. In the second attempt, two oocytes without ZP were retrieved with a midluteal short-acting GnRH agonist long protocol (Table 1; Figure 1D). We found a variant c. 400G > A (p. Ala134Thr) in exon 3 of the ZP3 gene. This variant was validated to be paternally inherited by Sanger sequencing (Figure 4B). PROVEAN, PolyPhen-2, and SIFT predicted the missense variant as pathogenic, and according to the ACMG criteria, the variant was classified as pathogenic (Tables 2, 3).

In family 8, the patient was a 32-year-old woman with a four-year history of primary infertility. The patient underwent two IVF/ICSI cycles. In her first cycle using an early-follicular phase long-acting GnRH agonist long protocol, eight oocytes were obtained: two were at the GV stage, five were at the MI stage, and one had no ZP formed. In her second attempt with a midluteal short-acting GnRH agonist long protocol, 12 oocytes were all at the GV stage. After IVM for 24 h, seven oocytes became mature, and 3 of them developed into two-pronuclei zygotes after fertilization, nevertheless no transferrable embryos in the end (Table 1). A heterozygous missense variant c.1543C > T (p.Pro515Ser) located in exon 14 of the ZP2 gene was detected (Figure 4C), which was not reported before. PROVEAN and PolyPhen-2 predicted the missense variant as pathogenic, and according to the ACMG criteria, the variant was classified as a variant of uncertain significance (Tables 2, 3). The conservation among primate species and the mutation location are indicated in Figures 4D,E. The results showed that mutation in ZP2 was highly evolutionarily conserved among different primate species.

Discussion

In our study, nine patients with oocyte maturation arrest were analyzed retrospectively, and the genetic etiology of oocyte maturation arrest was discussed. A total of nine variants in five genes, including PATL2, TUBB8, and ZP1∼3, were detected. All nine patients had oocyte arrest at different stages. We found three novel variants including c.1374A > G (p.Ile458Met) and 1289-1291del TCC(p.Leu430del) in the PATL2 gene and c.1543C > T (p.Pro515Ser) in the ZP2 gene. We also found that the patient with the variant [c.874C > T (p. Gln292*)] of ZP1 had a lack of ZP and EFS. Altogether, these nine variants were highly conserved among different species. The variants were rare in humans with allele frequency lower than 1% in ExAC Browser.

PATL2 gene c. 1374A > G (p. Ile458Met), which converts isoleucine to methionine, and c. 1289-1291delTCC (p. Leu430del) deletion lead to leucine deletion. The amino acid changes caused by these two variants are in the PAT1 domain (252–491amino acid), which contains 68% of the pathogenic variant of the PATL2 gene. It is responsible for the combination with mRNA. These mutations lead to the loss of PATL2 gene function and the decrease in the PATL2 protein expression. Because the oocyte maturation arrest type 4 is autosomal recessive inheritance, homozygous or compound heterozygous variant can lead to disease, while the patient’s mother can give birth normally. Marie Christou et al. sequenced mouse oocytes without the patl2 gene and found that the expression of genes related to oocyte maturation was significantly downregulated (Christou-Kent et al., 2018).

The variants of TUBB8 account for around 30% of females with oocyte maturation arrest (Feng et al., 2016a). In our study, TUBB8 gene c. 535G > A is a missense variant that causes valine to methionine, and variant c. 527C > G leads serine to tryptophan. These two variants are located in β-tubulin subunits. Mutations at these two sites affect protein folding and stability, as well as nucleotide binding. Variant c. 686T > C transforms valine to alanine, and c. 763G > A transforms valine to methionine. These two variants are located on the surface of microtubules and may interact with microtubule-related proteins, thus interfering with the regulation and stability of microtubules (Chen et al., 2017b). The pathogenicity of these variations has been reported, consistent with the results of previous studies (Chen et al., 2019; Feng et al., 2016a; Feng et al., 2016b; Huang et al., 2017), patients with TUBB8 mutations showed multiplicity phenotypes in oocytes and embryonic development, and the clinical characteristics of the oocytes retrieved from patients are summarized in Table1. We have five families with variations of the TUBB8 gene, and these patients have oocytes arrested at the MI stage or have some MII oocytes that can be fertilized, such as family 9. However, there were no transferable embryos after ICSI (Feng et al., 2016a).

We found variant c. 874C > T (p. Gln292 ∗) in exon 5 in the ZP1 gene, which results in an early termination of the codon and the termination of ZP1 protein synthesis at the 292nd amino acid encoded by exon 5. The complete ZP1 protein consists of 638 amino acids, of which there is a protein poly-nucleus composed of 279–549 amino acids, which is called the zona pellucida domain (Monné and Jovine, 2011). In humans, ZP is formed by the aggregation of ZP2, ZP3, and ZP4 proteins connected by the zona pellucida domain of ZP1 protein, and its mutation leads to premature termination resulting in ZP dysfunction (Lefièvre et al., 2004). In family 6, the patient with ZP1 mutation was absent of ZP around the oocytes in her second cycle, and EFS was manifested in the patient. In a recent study, they found a patient with compound heterozygous mutations in ZP1 (c.2T > A, p.M1K and c.1112+1G > T) had similar phenotype with EFS and defect in ZP (Liu et al., 2020). It suggested that the mutation of ZP1 may play an important role in EFS, not just resulting in the absence of ZP around the oocytes (Zhang et al., 2018). The variant c. 400G > A (p. Ala 134Thr) of ZP3 gene makes alanine to threonine, which is located in the ZP3 domain. The domain has eight conserved cysteine residues, and it is important for protein-protein interactions (Han et al., 2010; Monné et al., 2008). Previous studies have shown that this site mutation mainly destroys the assembly of ZP, resulting in oocyte degeneration and EFS (Chen et al., 2017c; Sirard et al., 2006). However, the mutation of this site leads to the formation of oocytes without ZP in our study. The patient’s father has a heterozygous mutation, and her mother was normal, so it affected the patient’s reproductive ability through dominant-negative effects. Variant c. 1543C > T of ZP2 changes proline into serine, which has not been reported. The point mutation is located in the zona pellucida domain of ZP2 gene which has a role in the formation of oocytes with ZP. Homozygous and compound heterozygous mutations of ZP2 may lead to oocyte maturation arrest in previous studies, including a thinner or absent ZP and IVF failure, following a recessive inheritance pattern. zp2 −/− mice produced few oocytes, with the oocytes exhibiting an extremely thin ZP, and they were not fertilized (Rankin et al., 2001). Zhou et al. found that the mutated ZP2 proteins might not be secreted to the surface of the oocyte, which might lead to the formation of a thin and defective ZP (Zhou et al., 2019). A study identified two homozygous pathogenic variants (c.1695-2A > G and c.1691_1694 dup, respectively) of ZP2 in infertile patients from two different consanguineous families: both resulted in a thin ZP and IVF failure (Dai et al., 2019). However, Yang et al. found the ZP2 variants inherited in an autosomal dominant pattern. The heterozygous variants c.1925G > A and the heterozygous variants c.1856T > A of ZP2 were detected in different patients with oocyte maturation arrest by WES, and they verified that heterozygous variant c.1925G > A caused altered protein modification and heterozygous variant c.1856T > A affected the intracellular transportation and secretion of ZP2 protein through in vitro experiments (Yang et al., 2021). We found the autosomal dominant pattern of ZP2 in family 8 with oocyte maturation arrest as well.

However, there are several limitations of the current study. Firstly, the gDNA of parents were unavailable in some families, so we cannot determine whether the variant is de novo or inherited. Additionally, further functional studies should be performed to prove that these mutations affect protein function.

In conclusion, we found three novel variants in two families and analyzed the genetic causes of oocyte maturation arrest. Our study expands the spectrum of the ZP2 and PATL2 gene mutations. Due to the rare occurrence of these patients, future research is warranted to verify. As for the treatment of these patients, the best alternative is oocyte donation in view of this cause at present.